ACS Appl Bio Mater

1. CHEN Z, Li J, Hu H, Zhang Y, et al
   Biocompatible HA-PBA/PVA Dual-Network Hydrogel Composite System: A Promising Localized Therapeutic Platform for Bladder Cancer.
   ACS Appl Bio Mater. 2026 Sep 4. doi: 10.1021/acsabm.6c01346.
   

   >> Share

   
   

   
   Actas Urol Esp (Engl Ed)

2. AYDIN YM, Ozdel O, Mungan NA
   Clinical and tumor-related determinants of early morbidity and prolonged hospital stay after TUR-BT.
   Actas Urol Esp (Engl Ed). 2026;50:501987.
   

   >> Share

   
   
3. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
   Improving long-term monitoring in NMIBC: Digital Uromonitor(R) (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification.
   Actas Urol Esp (Engl Ed). 2026;50:501994.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

4. YUAN Q, Song T, He Y, Xia S, et al
   AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.
   Adv Sci (Weinh). 2026 Aug 30:e77479. doi: 10.1002/advs.77479.
   

   >> Share

   
   

   
   AJR Am J Roentgenol

5. OBMANN MM
   Low-keV Reconstructions, No Extra Scan: Photon-Counting CT's Case for Bladder Cancer Local Staging.
   AJR Am J Roentgenol. 2026 Sep 2. doi: 10.2214/AJR.26.35798.
   

   >> Share

   
   

   
   Am J Surg Pathol

6. DOWNES MR, Wobker SE, Smith SC, Eckstein M, et al
   International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer: Working Group 2: The Urinary Bladder.
   Am J Surg Pathol. 2026 Sep 2. doi: 10.1097/PAS.0000000000002613.
   

   >> Share

   
   

   
   Arch Esp Urol

7. KORKES F, Galdino M, Burger H, Archila D, et al
   Conversion From Cutaneous Ureterostomy to Ileal Conduit in Frail Patients: A Descriptive Case Series.
   Arch Esp Urol. 2026;79:1264-1268.
   

   >> Share

   
   

   
   BMC Med

8. RICHTMANN S, Radak M, Sincic V, Hugoson J, et al
   Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation.
   BMC Med. 2026;24:468.
   

   >> Share

   
   

   
   BMC Urol

9. UZUN E, Ozen S, Senel S, Arabaci HB, et al
   Variant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy.
   BMC Urol. 2026;26:213.
   

   >> Share

   
   

   
   Br J Cancer

10. ZUIDEMA A, Nijland L, van Megesen K, Vosjan MM, et al
    ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.
    Br J Cancer. 2026 Aug 31. doi: 10.1038/s41416-026-03581.
    

    >> Share

    
    

    
    Can J Urol

11. KHALID U, Shah N, Kavia R, Batura D, et al
    Artificial intelligence advances in cystoscopy and imaging for bladder cancer: a narrative review.
    Can J Urol. 2026;33:735-752.
    

    >> Share

    
    
12. MANIVASAGAM SS, Clark JY, Raman JD
    Unintended consequences of antibiotic practices: the relationship between bowel preparation, prolonged prophylaxis, and ileus after radical cystectomy.
    Can J Urol. 2026;33:865-871.
    

    >> Share

    
    

    
    Cancer Immunol Res

13. PERICART S, Tosolini M, Roumiguie M, Saint A, et al
    A High Density of Impaired Tertiary Lymphoid Structures Is Associated with Higher Tumor Stage and Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-26-0104.
    

    >> Share

    
    

    
    Cancer Med

14. ODAGIRI K, Morikawa T, Naiki T, Sugiyama Y, et al
    Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
    Cancer Med. 2026;15:e72252.
    

    >> Share

    
    

    
    Colloids Surf B Biointerfaces

15. ZHOU FY, Wang J, Xu R, Yang LW, et al
    Smart nanoplatform based on mesoporous polydopamine for combined photothermal-chemotherapy in the treatment of urothelial carcinoma.
    Colloids Surf B Biointerfaces. 2026;268.
    

    >> Share

    
    

    
    Cureus

16. HERVER VAZQUEZ ME, Mora Montoya MJ, Coria Dominguez LA, Granados Sanchez EF, et al
    Radiotherapy for Metastatic Bladder Cancer in the Era of Modern Systemic Therapies.
    Cureus. 2026;18:e113796.
    

    >> Share

    
    
17. OSKA C, Mehta KJ, Simone CB 2nd, Hsieh K, et al
    Proton Therapy for Muscle-Invasive Bladder Cancer: Outcomes from the Multicenter Proton Collaborative Group PCG 001-09 Registry Trial.
    Cureus. 2026;18:e113689.
    

    >> Share

    
    

    
    Diagn Cytopathol

18. TERAUCHI T, Nguyen TT, Takata M, Shimizu R, et al
    Clinical and Cytopathological Significance of Intracytoplasmic Lumina and Immunohistochemical Mucin Expression in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Diagn Cytopathol. 2026;54:764-772.
    

    >> Share

    
    

    
    Eur Urol Oncol

19. DEHGHANPOUR A, Pecoraro M, Zhang GM, Borrelli A, et al
    VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification.
    Eur Urol Oncol. 2026;9:930-937.
    

    >> Share

    
    
20. COMPERAT EM, Hartmann A, Allory Y, Bellosillo B, et al
    FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.
    Eur Urol Oncol. 2026;9:977-985.
    

    >> Share

    
    
21. DILLON R, Jones R, Flechon A, Chan K, et al
    Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy +/- Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.
    Eur Urol Oncol. 2026;9:938-945.
    

    >> Share

    
    
22. GONTERO P, Soria F, Babjuk M, Burger M, et al
    Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.
    Eur Urol Oncol. 2026;9:868-882.
    

    >> Share

    
    
23. PFISTER C, Harter V, Fontugne J, Allory Y, et al
    Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor.
    Eur Urol Oncol. 2026;9:795-803.
    

    >> Share

    
    
24. TEOH JY, Wong CH, Cheng CH, Tsang CF, et al
    Impact of Intravesical Bacillus Calmette-Guerin Therapy Following Transurethral En Bloc Resection of Bladder Tumour: Post Hoc Analysis of a Randomised, Multicentre, Phase 3 Trial.
    Eur Urol Oncol. 2026;9:761-765.
    

    >> Share

    
    
25. SILCOCK L, Hastings RK, Clokie S, Sadler R, et al
    Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics.
    Eur Urol Oncol. 2026 Sep 2:S2588-9311(26)00233-6. doi: 10.1016/j.euo.2026.
    

    >> Share

    
    
26. CONTIERI R, Hurle R
    Reply to Francesco Di Bello, Andrea Gallioli, Joan Palou, and Alberto Breda's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients
    Eur Urol Oncol. 2026 Sep 5:S2588-9311(26)00240-3. doi: 10.1016/j.euo.2026.
    

    >> Share

    
    

    
    Front Cell Infect Microbiol

27. SHENG Z, Zhu J, Sun J, Zeng S, et al
    Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential.
    Front Cell Infect Microbiol. 2026;16:1890640.
    

    >> Share

    
    

    
    Front Oncol

28. ZHAO M, Wu Y, Luo B, Long J, et al
    Prognostic value of preoperative systemic immune-inflammation index in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1909255.
    

    >> Share

    
    

    
    Front Pharmacol

29. LIU K, Xu F, Wu C, Wang M, et al
    Mechanisms of resistance to antibody-drug conjugates in bladder cancer.
    Front Pharmacol. 2026;17:1882868.
    

    >> Share

    
    

    
    Front Public Health

30. TAN S, Nie C, Yang S, Dai C, et al
    Sexual life and intimate relationship experience among bladder cancer patients: a systematic review and qualitative meta-synthesis.
    Front Public Health. 2026;14:1887122.
    

    >> Share

    
    

    
    Gene

31. KRUITHOF-DEJULIO M
    Editor's corner: Heavy metal exposure and the epigenetic landscape of urothelial bladder cancer.
    Gene. 2026 Sep 3:150377. doi: 10.1016/j.gene.2026.150377.
    

    >> Share

    
    

    
    Int J Clin Oncol

32. NAKAYASU R, Hamada A, Sakatani T, Mizuno K, et al
    Adverse event-related discontinuation of maintenance Bacillus Calmette-Guerin therapy and oncological outcomes in non-muscle-invasive bladder cancer.
    Int J Clin Oncol. 2026 Sep 2. doi: 10.1007/s10147-026-03179.
    

    >> Share

    
    

    
    Int J Surg

33. ZHANG Q, Zhao N, Song K, Ye X, et al
    SurvGRN: a multi-feature fusion framework for bladder cancer survival prediction.
    Int J Surg. 2026;112:13092-13104.
    

    >> Share

    
    
34. XIAO Y, Zhang X, Xie Z, Tao L, et al
    Potential of RAD51C as a hub gene and therapeutic target in bladder cancer: insights from bioinformatics and experimental analysis.
    Int J Surg. 2026;112:13049-13072.
    

    >> Share

    
    
35. LIU S, Wang Y, Peng S, Wang J, et al
    RUNX3+ basal-like malignant cells: architects of an immunosuppressive microenvironment in bladder cancer: a comprehensive bioinformatics analysis of single-cell and spatial transcriptomics.
    Int J Surg. 2026;112:13034-13048.
    

    >> Share

    
    

    
    Int Urol Nephrol

36. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis.
    Int Urol Nephrol. 2026 Sep 4. doi: 10.1007/s11255-026-05373.
    

    >> Share

    
    

    
    Investig Clin Urol

37. COSTA TM, Demartino G, de Toledo LGM, Vetorazzi GD, et al
    Intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context.
    Investig Clin Urol. 2026;67:431-440.
    

    >> Share

    
    
38. LEE HW, Song G, Lee HH, Jung EH, et al
    Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial.
    Investig Clin Urol. 2026;67:441-451.
    

    >> Share

    
    

    
    J Pediatr Urol

39. SAO LEAO RIBEIRO LC, Araujo Matalani CF, Vilares RN, Suartz CV, et al
    Neoplasms in prune belly syndrome: A novel case of early-onset metastatic bladder carcinoma and systematic review of reported tumors.
    J Pediatr Urol. 2026;22:106048.
    

    >> Share

    
    

    
    J Urol

40. CLARK PE, Holzbeierlein J, Chang SS, Djaladat H, et al
    2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    J Urol. 2026 Sep 4:101097JU0000000000005280. doi: 10.1097/JU.0000000000005280.
    

    >> Share

    
    

    
    JAMA Netw Open

41. SHAH KU, Jaime-Casas S, Agarwal R, Zhang G, et al
    Regional Variation in Bladder Cancer Clinical Trial Availability in the US.
    JAMA Netw Open. 2026;9:e2632012.
    

    >> Share

    
    

    
    Mil Med Res

42. CHO WC
    Enhanced CT-based deep learning radiomics for bladder cancer prognosis.
    Mil Med Res. 2026;13:100065.
    

    >> Share

    
    

    
    Mol Biol Rep

43. KIVANC D, Erdem S, Hurdogan O, Ciftci HS, et al
    The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer.
    Mol Biol Rep. 2026;53:1489.
    

    >> Share

    
    

    
    Mol Imaging Biol

44. FIZ F, Bottoni G, Boitano M, Ugolini M, et al
    [(64)Cu]CuCl(2) as a Novel Metabolic Marker of Progression and Survival in Muscle-Invasive Bladder Cancer.
    Mol Imaging Biol. 2026 Sep 2. doi: 10.1007/s11307-026-02135.
    

    >> Share

    
    

    
    Nat Rev Urol

45. LI C, Hu Z, Zhang W, Ji Y, et al
    Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.
    Nat Rev Urol. 2026;23:607-620.
    

    >> Share

    
    

    
    Oncogene

46. WEI H, Bai R, Liu J, Lyu L, et al
    POC1A promotes the proliferation, metastasis and stemness of bladder cancer by stabilizing BMI1 via USP7.
    Oncogene. 2026 Aug 31. doi: 10.1038/s41388-026-03973.
    

    >> Share

    
    
47. ZHAO Y, Xing Z, Wang M, Fu L, et al
    DHCR24(+) tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling.
    Oncogene. 2026 Aug 29. doi: 10.1038/s41388-026-03967.
    

    >> Share

    
    

    
    Sci Rep

48. MAEDA S, Yokota S, Komori M, Goto-Koshino Y, et al
    Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.
    Sci Rep. 2026;16:24028.
    

    >> Share

    
    
49. MAIORANO BA, Roviello G, Rizzo A, Ciccimarra F, et al
    Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.
    Sci Rep. 2026;16:27711.
    

    >> Share

    
    

    
    Ther Adv Urol

50. ITO W, Tachibana I
    Biomarker-guided selection of intravesical therapy in high-risk non-muscle invasive bladder cancer: A contemporary review.
    Ther Adv Urol. 2026;18:17562872261485770.
    

    >> Share

    
    
51. WILLIAMS C, Shah Y, Xia L
    Perioperative treatment for muscle invasive bladder cancer in the era of immunotherapy.
    Ther Adv Urol. 2026;18:17562872261481954.
    

    >> Share

    
    

    
    Transl Oncol

52. WANG Q, Wang D, Jiang H, Min J, et al
    Cancer-associated fibroblasts-derived CAV1 promotes epithelial-mesenchymal transition and stemness in bladder cancer through activation of the LIF/STAT3 signaling pathway.
    Transl Oncol. 2026;73:103001.
    

    >> Share

    
    

    
    Vet Pathol

53. CORBETT MP, Elbadawy M, Woodward AP, Cheville JC, et al
    Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma.
    Vet Pathol. 2026;63:807-819.
    

    >> Share

    
    

    
    World J Urol

54. CAO Q, Liu H, Xu Y, Wang Y, et al
    Using human proteomic and lipidomic to exploration drug target of bladder cancer.
    World J Urol. 2026;44:619.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share